Q-omics provides the consensus-scored SPATA22 profile across patient tissues and cancer cell-line models. SPATA22 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPATA22 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, SPATA22 RNA expression shows 8,045 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BLCA, and TGCT as cancer lineages where SPATA22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA22 survival associations across molecular data types. SPATA22 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA22 RNA expression–survival associations across cancer types. High SPATA22 expression shows unfavorable associations in ACC and COAD, but favorable associations in SKCM, LUAD, ESCA and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPATA22 RNA expression.
This table summarizes SPATA22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA22 shows lower tumor expression in BLCA, KICH, COAD, BRCA, UCEC and KIRP. The BLCA box plot shows higher SPATA22 RNA expression in normal versus tumor tissue (log2 FC = −0.250, t-test p = .003).
This table shows molecular features associated with SPATA22 in patient tissues and cancer cell lines. In patient samples, SPATA22 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
